Found 3290 clinical trials
A Trial Evaluating Different Dosing Durations of TEPEZZA® Treatment in Patients with Thyroid Eye Disease (TED)
The overall objective is to investigate the safety, tolerability and need for re-treatment of 3 different TEPEZZA® treatment durations (4, 8, or 16 infusions) in patients with TED.
- 0 views
- 20 May, 2022
- 2 locations
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)
The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …
- 0 views
- 20 May, 2022
- 10 locations
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a
- 0 views
- 27 May, 2022
- 1 location
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The goal is to determine the efficacy, safety and tolerability for 300 patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)), or a placebo regimen for 52 weeks.Participants who complete all study visits may …
- 0 views
- 20 May, 2022
- 35 locations
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
- 0 views
- 27 May, 2022
- 137 locations
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule. With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will
- 182 views
- 10 May, 2022
- 35 locations
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
. This study consists of 3 cohorts, Cohorts A, B, and C, and will enroll approximately 82, 82, and 25 participants into each cohort, respectively. Participants will receive pemigatinib 13.5 mg QD on a 2
- 0 views
- 25 May, 2022
- 1 location
Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- 133 views
- 22 Feb, 2019
- 1 location
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) on slowing progression of mild cognitive impairment due to Alzheimer's disease
A study for patients with mild cognitive impairment due to Alzheimer's disease with short memory loss.
- 159 views
- 08 Dec, 2020
- 1 location
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL-GROUP, 52-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF SIMUFILAM 100 MG TABLETS IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
to a placebo. A placebo is a pill that looks exactly like the study medicine but does not contain any active ingredient.In this study, you will take either simufilam 100 mg or
- 0 views
- 25 Mar, 2022
- 1 location